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Abstract. Caveolin-1 (Cav-1) expression has been shown to be 
associated with tumor growth and resistance to chemotherapy 
in pancreatic cancer. The primary aim of this study was to 
explore the significance of Cav-1 expression in pancreatic 
cancer cells as compared to fibroblasts in relation to cancer cell 
proliferation and chemoresistance, both in vitro and in vivo, in 
an immunodeficient mouse model. We also aimed to evaluate 
the immunohistochemical expression of Cav-1 in the epithelial 
and stromal component of pancreatic cancer tissue specimens. 
The immunohistochemical staining of poorly differentiated 
tissue sections revealed a strong and weak Cav-1 expression in 
the epithelial tumor cells and stromal fibroblasts, respectively. 
Conversely, the well-differentiated areas were characterized 
by a weak epithelial Cav-1 expression. Cav-1 downregulation 
in cancer cells resulted in an increased proliferation in vitro; 
however, it had no effect on chemoresistance and growth 
gain in vivo. By contrast, the decreased expression of Cav-1 
in fibroblasts resulted in a growth advantage and the chemo-
resistance of cancer cells when they were co-injected into 
immunodeficient mice to develop mixed fibroblast/cancer cell 
xenografts. On the whole, the findings of this study suggest 
that the downregulation of Cav‑1 in fibroblasts is associated 
with an increased tumor proliferation rate in vivo and chemo-
resistance. Further studies are warranted to explore whether 
the targeting of Cav-1 in the stroma may represent a novel 
therapeutic approach in pancreatic cancer.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) remains one 
of the most lethal types of cancer with little improvement 
in the survival rates over the past decades. It is the fourth 
leading cause of cancer-related mortality in the USA and in 
Europe (1). The prognosis of patients with this disease remains 
unfavorable for all stages of the disease with the 5-year overall 
survival rate being <5% (2). Surgical resection, followed 
by adjuvant therapy, is the only radical therapeutic option; 
however, <15% of patients present with operable disease. 
Patients with advanced disease at presentation or recurrence 
may receive palliative chemotherapy, although the rates of 
response and survival benefit is modest. Aggressive tumor 
biology, as well as primary or secondary drug resistance (3) 
contribute significantly towards this dismal prognosis.
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Caveolin-1 (Cav-1) is a 22-kDa molecular weight integral 
cell membrane scaffolding protein and a main component of 
caveolae, which are transmembrane microdomains composed 
of cholesterol and sphingolipids thus known as ‘lipid rafts’. This 
protein, in one of two similar isoforms (Cav-1a and Cav-1b), 
is associated with the processes of endo- and exocytosis, and 
with intracellular signal transduction mechanisms (4). Cav-1 is 
involved in a number of biological processes, as well as cellular 
transformation, tumorigenesis and metastasis (5). Cav-1 protein 
allows for signaling transduction events associated with the 
epidermal growth factor receptor (EGFR), HER2/neu, Src, 
the focal adhesion-associated protein kinase (FAK) and the 
mitogen-activated protein kinase (MAPK) (6). In addition, 
through its interaction with the adhesion molecules of the 
extracellular matrix, the integrins, it seems to be associated 
with the induction of the apoptosis of cancer cells (7,8).
Of note, Cav-1 appears to play a dual role in cancer 
biology (9). Its expression in cancer cells has been associated 
with an aggressive phenotype and a poor prognosis in various 
tumor types, including pancreatic adenocarcinoma (10-14). It has 
also been directly linked to the metastatic potential of pancreatic 
cancer cells through the regulation of epithelial to mesenchymal 
transition (EMT), a phenomenon closely related to the meta-
static potential and chemoresistance of cancer cells (15,16). 
Nevertheless, conflicting results have been presented (17), with 
the loss of Cav-1 in the tumor stroma being associated with an 
adverse clinical outcome in a variety of cancer types (18-23).
Previous studies have implicated Cav-1 protein as an 
important factor in the development of chemo - and radio-
resistance (24,25), while complex interactions seem to be 
involved in the role of Cav-1 in the development of multi-drug 
resistance (MDR) (26). To date, there are no consistent data 
implicating Cav-1 in the development of chemoresistance in 
pancreatic adenocarcinoma (27-29). Moreover, it is not clear 
whether the expression of Cav-1 in pancreatic cancer cells or 
cancer‑associated fibroblasts (CAFs) is predictive of the treat-
ment response or overall prognosis (10,21,30).
The purpose of this study was to examine the role of Cav-1 
in the development of chemoresistance in pancreatic cancer. 
Initially, we examined the differential immunohistochemical 
expression of Cav-1 between tumor and stromal cells in human 
pancreatic cancer tissue specimens. We then examined the 
response of human pancreatic cancer cell lines, with differ-
ential expression levels of Cav-1, to chemotherapeutic agents 
both in vitro and in vivo using pancreatic cancer animal 
models developed in immunodeficient mice. Furthermore, 
and in order to shed light on the role of Cav-1 expression in 
the context of the tumor microenvironment, we generated and 
used fibroblasts with a decreased expression of Cav‑1. Our 
results indicate that expression of Cav-1 in tumor cells per se 
may play a minor role in their tumorigenicity and chemoresis-
tance. However, the decreased expression of this protein in the 
tumor microenvironment i.e., in fibroblasts, seems to result in 
increased tumorigenic properties of cancer cells together with 
increased chemoresistance.
Materials and methods
Materials. RPMI-1640 and DMEM were purchased 
from Gibco/Thermo Fisher Scientific (Athens, Greece) 
and L-glutamine, PBS and trypsin were purchased 
from GE Healthcare Life Sciences (GE Healthcare Life 
Sciences/Athal, Athens, Greece). Fetal bovine serum was 
purchased from Biowest (Biowest/Bioline Scientific, Athens, 
Greece) and dimethylsulphoxide (DMSO) from Eastman Kodak 
(Columbus, GA, USA). Trichloroacetic acid (TCA), TEMED, 
hydrochloric acid, SDS, hydrogen peroxide, glycerol 99.9%, 
sulphorodamine-B for the in vitro cytotoxic assay, NP40 and 
protease inhibitors were obtained from Sigma-Aldrich (Merck, 
Chemilab S.A., Athens, Greece). 2-β-mercaptoethanol was 
purchased from Merck (Chemilab S.A.) while Ponceau S 
staining solution and Triton X-100 were from AppliChem 
(AppliChem GmbH, Darmstadt, Germany). Glycine ≥99% 
was purchased from Roth (Karlsruhe, Germany) while 
protein electrophoresis markers, SDS acrylamide 30% and the 
Quick Start Bradford Dye reagent 1X for the measurement of 
protein content of our samples were purchased from Bio-Rad 
Laboratories Ltd. (Athens, Greece). All the chemotherapeutic 
agents [5‑fluorouracil (5‑FU), gemcitabine, doxorubicin, epiru-
bicin, cisplatin, oxaliplatin, docetaxel and Paclitaxel] were 
kindly provided by the Oncology Department of the General 
University Hospital of Larissa, Larissa, Greece. Cell culture 
plastic products were all purchased from Sarstedt (Sarstedt 
Ltd., Athens, Greece).
Cell culture. BxPC3 (pancreatic adenocarcinoma), AsPC1 
(pancreatic adenocarcinoma metastatic), PANC-1 (epithe-
lioid carcinoma from pancreatic duct) and MIAPaCa-2 
(pancreatic carcinoma) cancer cell lines were obtained from 
ATCC (Manassas, VA, USA). Human dermal fibroblasts 
were obtained originally from Thermo Fisher Scientific 
(Loughborough, UK). The cancer cells were adapted to prolif-
erate in RPMI‑1640 medium and the fibroblasts in DMEM, 
supplemented with 5% heat-inactivated fetal calf serum, 
2 mM L-glutamine and antibiotics. The cultures were grown 
at 36.7˚C in a humidified incubator with 5% CO2 atmosphere 
and 95% humidity.
Silencing of Cav‑1 in BxPC3 cells. To minimize the differences 
between various cell lines, we set out to induce the stable 
knockdown of Cav-1 in BxPC-3 cells that naturally express 
high levels of Cav-1. Hence, we measured their proliferative 
capacity, their migratory capacity and chemosensitivity. We 
induced the stable knockdown through lentiviral infection, 
which also allowed tracking the cells containing the virus 
due to constitutive green fluorescent protein (GFP) expression 
(fluorescent in the green channel). Cav-1 expression was 
silenced by transduction with short hairpin RNA (shRNA)
mir GIPZ lentiviral particles (Open Biosystems, Surrey, UK). 
The cells were seeded at 50% confluence and infected by 
direct contact with lentiviral particles diluted 1:50 into 1 ml of 
serum-free RPMI-1640 and incubated for 6 h, following which 
an additional 1 ml of 10% RPMI-1640 was added and the cells 
were incubated for a further 72 h. The transduction efficiency 
was evaluated by GFP co-expression by a fluorescence 
microscope (EVOS™ FL Imaging System; Τhermo Fisher 
Scientific, Loughborough, UK). Stably transduced cells were 
then selected in media containing 1.0 µg/ml puromycin (Life 
Technologies/Thermo Fischer Scientific, Athens, Greece) for 
10 days.
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To purify further and homogenize the cellular populations, 
cells transduced as described above were sorted on a 
BD FACS-Vantage cell sorter (Becton-Dickinson, Oxford, 
UK) based on GFP expression. Through this procedure, 
employing silencing shRNA for caveolin, the cell line named 
BxPC3shCAV was finally generated, while a mock‑transfected 
cell line named BxPC3mock was also generated to be used as 
control. These cells were used for the experiments described 
further in this study.
Immortalization of human dermal fibroblasts and silencing 
of Cav‑1. For immortalization, pBabe hTERT geneticin retro-
virus supernatant (Addgene, Cambridge, MA, USA) was used 
to transduce human dermal fibroblasts at 50% confluence. 
After 24 h, the cell media were changed and the cells were 
cultured for a further 48 h. Selection was carried out for 4 days 
with 1.0 µg/ml geneticin (Life Technologies; Thermo Fisher 
Scientific, Loughborough, UK). The hTERT-immortalized 
human skin fibroblasts named hhsF from hereon were used in 
the further experiments.
Cav-1 expression was silenced as described above. Two 
types of hhsF were developed: The hhsFmock and the hhsFshCAV 
with unaffected levels of Cav-1 or with silenced Cav-1, 
respectively.
Western blot analysis. For western blot analysis cancer 
cells were cultured in 6-well plates at inoculation densities 
varying from 4x106 to 6x106/ml, depending on the cell line. 
After 24 h, the cells were washed twice in ice-cold PBS, 
trypsinized, collected by gentle centrifugation, and whole cell 
protein extracts were prepared as previously described (31). 
Protein concentrations were determined with the Bradford 
assay, and subsequently, aliquots containing 30 µg of protein 
were subjected to gel electrophoresis on 10% polyacylamide 
SDS-gels under reducing conditions, and then transferred onto 
PVDF membranes (Millipore Immobilon; Merck S.A. Hellas, 
Athens, Greece). To confirm protein transfer, the membranes 
were stained with Ponceau S solution (AppliChem GmbH). 
Finally after the washing membranes to remove the Ponceau S, 
the proteins were visualized using an enhanced chemolumi-
nescence detection system (Amersham ECL or ECL Plus, 
GE Healthcare Life Sciences) according to the manufacturer's 
instructions. Cav-1 antibody was purchased from Santa Cruz 
Biotechnology (clone N-20, sc-894; Heidelberg, Germany) 
while, actin antibody was purchased from Sigma-Aldrich 
(Life Science Chemilab S.A., Athens, Greece) and GAPDH 
antibody from BioLegend (San Diego, CA, USA). Anti-rabbit 
and anti-mouse HRP conjugated secondary antibodies used 
were purchased from Sigma-Aldrich. Antibodies were used as 
follows (all were diluted in Tris-buffered saline supplemented 
0.05% Tween-20 and 5% FCS): CAV-1 at 1:500 (overnight 
incubation at 4˚C), GAPDH at 1:6,000 (2 h at room tempera-
ture), actin at 1:2,000 (2 h at room temperature), and both 
secondary antibodies at 1:6,000 (1 h at room temperature).
RNA isolation and RT‑qPCR analysis. Total RNA was isolated 
using the RNeasy Mini kit (Qiagen, Valencia, CA, USA) 
according to the manufacturer's instructions. One microgram 
of total RNA from each sample was retro-transcribed to 
first‑strand cDNA using the SuperScript III One Step RT‑PCR 
system (Invitrogen/Thermo Fisher Scientific, Loughborough, 
UK). Quantitative RT-PCR was performed in triplicates using 
SYBR-Green RT-PCR Master Mix kit and the ABI PRISM 7500 
Fast Real-Time PCR System (Applied Biosystems/Thermo Fisher 
Scientific, Loughborough, UK) with the following primers: 
Cav-1, 5'-CGACCCTAAACACCTCAACGA-3' (forward) and 
5'‑TCCCTTCTGGTTCTGTCA‑3' (reverse). Quantification was 
performed using the comparative CT (cycle-threshold) method 
employing ribosomal 18S as a housekeeping gene (ΔΔCq 
method) (32).
Evaluation of cell proliferation [bromodeoxyuridine (BrdU) 
assay]. Cell proliferation was evaluated by determining the 
incorporation of BrdU nucleotide in actively proliferating 
cells, using a colorimetric ELISA (Abcam, Cambridge, UK). 
The assay was performed as per the manufacturer's instruc-
tions. The colored reaction product was quantified using a 
spectrophotometer (microplate reader, BioTek EL-311; BioTek 
Instruments, Bad Friedrichshall, Germany).
Wound healing/scratch assay. To determine the effects of 
Cav-1 on the ability of cancer cells to migrate in vitro, we 
utilized the scratch assay. In the monolayer of cells covering 
approximately the 80% of the microtiter plate well surface, a 
scratch was made using a sterile 200 µl pipette tip. Following 
a wash with PBS and the addition of fresh growth medium, 
the cells were allowed to migrate for 24 or 48 h. The cells 
were photographed using a light microscope and a x10 magni-
fication (Axioplan equipped with an AxioCam, Zeiss Ltd., 
Cambridge, UK) at various time points i.e., 0, 5, 9 14 and 28 h 
to analyze the migration of the cells towards the 'wounded' 
area.
Chemotaxis/migration assay. To determine the ability of fibro-
blasts to induce the chemotactic migration of the BxPC3 cancer 
cells, 24 mm Transwell® with 8.0-µm pore polycarbonate 
membrane inserts (Product #3428, Corning® Transwell®; 
Sigma-Aldrich; Merck, Chemilab S.A.) was used. The chemo-
taxis/migration assay was performed as follows:
At day zero, a 24-well migration plate was inoculated 
with the fibroblasts (hhsFmock or hhsFshCAV) at a density of 
20x103 cells/well in 500 µl of serum-free DMEM, and the 
cells were allowed to adapt in a 5% CO2 incubator at 36.7˚C 
for 48 h. Subsequently, the medium was removed and DMEM 
supplemented with 10% FCS (10% DMEM) was added 
for 12 h to serum-activate the fibroblasts, as previously 
described (33). Thereafter, the 10% DMEM medium was 
removed, and the fibroblasts were washed twice with PBS 
and 500 µl of DMEM supplemented with 1% FCS was added. 
Following a further 12 h of incubation, a cell suspension of 
BxPC3 cells at a density of 60x104 cells/ml in serum-free 
media was prepared. A Transwell® insert was then applied 
to the fibroblast‑containing wells and 250 µl of the BxPC3 
cells suspended in serum-free media were then added to the 
insert. Wells containing 1% DMEM underneath the insert 
were used as negative controls in order to determine the 
spontaneous migration of BxPC3 cells under these conditions, 
while wells with 10% DMEM underneath the insert served as 
positive controls. Incubation continued (5% CO2, 36.7˚C) for a 
further 12 h. Next, the media from the inside of the insert were 
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carefully aspirated, the inserts removed from the culture plates 
and non-migratory cells were removed from the interior of the 
inserts with cotton-tipped swabs. Subsequently, the inserts 
were transferred to a clean well containing 400 µl of ice-cold 
TCA to fix the cells attached to the outer surface of the insert 
as described for the cytotoxicity assay. The fixed inserts were 
gently washed several times in distilled water, air-dried and 
stained with sulforhodamine B (SRB) as for the in vitro cyto-
toxic activity assay described below. After a second wash step 
to remove any unbound staining, the inserts were transferred 
to a clean plate containing 400 µl of unbuffered Tris to extract 
the dye and 200 µl of the solution was transferred to a 96-well 
plate and finally the OD value was measured using a micro-
plate reader (Biotek EL-311; BioTek Instruments). Chemotaxis 
was calculated as the % OD value of the inserts as compared 
to inserts containing no fibroblasts (negative controls). For 
chemotaxis, two independent experiments were performed.
In vitro cytotoxic activity of chemotherapeutic drugs. The in vitro 
cytotoxic activity of all chemotherapeutics tested herein [5‑fluo-
rouracil (5-FU), gemcitabine, doxorubicin, epirubicin, cisplatin, 
oxaliplatin, docetaxel and Paclitaxel] was determined using the 
SRB assay, as previously described (34,35). Cell viability was 
assessed at the beginning of each experiment by the trypan blue 
dye exclusion method, and was always >97%. For the SRB assay, 
the cells seeded into 96-well plates in 100 µl medium at a density 
of 5,000 cells per well, and incubated under standard conditions 
for 24 h to enable the cells to resume exponential growth before 
addition of the compounds. In order to measure the starting cell 
population [time zero (Tz)], cells in one plate were fixed in situ 
with TCA 50%. Compounds were diluted to twice the desired 
final maximum test concentration (100 µM for all other drugs, 
but for paclitaxel and docetaxel the maximum concentrations 
tested were 10 µM) with complete medium and 4 or 5 addi-
tional 10-fold dilutions, depending on the drug, were prepared. 
Aliquots of 100 µl of these different drug dilutions were added 
to the appropriate microtiter wells already containing 100 µl of 
medium, resulting in the required final drug concentrations. Cell 
cultures containing DMSO alone served as negative controls, 
while as a positive control, control representative wells were 
treated with a corresponding volume of culture medium.
Following drug addition, the plates were incubated for 48 h 
at the conditions described above. The experiment was termi-
nated by the addition of 50 µl of cold 50% (w/v) TCA (final 
concentration, 10% TCA). Incubation for 1 h at 4˚C and staining 
with SRB was carried out as previously described (34,35). 
The bound stain was subsequently solubilized with a 10 mM 
Trizma base (Sigma-Aldrich; Merck, Chemilab) and the absor-
bance was read on an automated plate reader, EL-311 (BioTek 
Instruments), at a 530 nm wavelength.
Using the absorbance measurements [time zero (Tz), 
control growth (C), and test growth in the presence of drug 
at the 5 concentration levels (Ti)], the growth percentage of 
the cells was calculated for each drug concentration using the 
following formulas: i) [(Ti-Tz)/(C-Tz)] x 100 for concentrations 
for which Ti>/=Tz and ii) [(Ti-Tz)/Tz] x 100 for concentrations 
for which Ti<Tz.
In vivo experiments. To generate human-to-mouse pancreatic 
cancer xenografts, 5x106 cells from exponentially growing 
cultures of BxPC3mock or BxPC3shCAV cells were injected subcu-
taneously, according to the British practice of bilateral implants, 
at the axillary region of the rear flanks into 6‑8‑week‑old (mean 
weight, 20 g) female NOD.CB17-Prkdcscid/J (NOD/SCID) 
mice from our animal facility (EL 42 BIO_BR01). During 
experimentation, all animals were kept in the Animal 
Unit of the Department of Pharmacology (University of 
Thessaly, Larissa Greece; EL42 BIO_EXP03) under specific 
pathogen-free (SPF) conditions, a 12-h/12-h light/dark, a 
temperature of 21˚C and a relative humidity 50% and allowed 
access to water and food ad libitum. For the co-injection of 
fibroblasts with BxPC3 (3x105) cells at the exponential growth 
phase, hhsFmock or hhsFshCAV fibroblasts were co‑injected with 
BxPC3 cells at 1:1 or 1:3 ratios, respectively in plain DMEM, 
subcutaneously at the axillary region of the rear flanks of 
mice (two injections per mouse as described above for the 
generation of BxPC3mock or BxPC3shCAV xenografts). In this 
experiment a group of mice received 3x105 fibroblasts alone, 
as well, to determine whether the transformed fibroblasts had 
any tumorigenic capacity. Each group consisted of 5 mice of 
matching age and weight. The mice were then followed for the 
development of tumors. At the end of the experiment, which 
varied depending on the specific group (i.e., for the generation 
of BxPC3mock or BxPC3shCAV the experiment ended at day 65 
post-tumor cell inoculation, for the development of co-injected 
xenografts experiments ended at days 26-28 post-tumor cell 
inoculation) the mice were euthanized (age, 12-16 weeks; mean 
weight, 20-22 g) and the tumors were removed and weighed. 
Where tumor volume was used this was calculated according 
to the formula [(axb2)/2], where a=length and b=width of the 
tumor as measured with a Vernier's caliper (measurements 
were performed twice a week).
Animals treated with gemcitabine received an intra-
peritoneal injection/week at a 100 mg/kg dose until the end 
of experiment. Treatment began 4 days after cell implantation. 
Weight loss (assessed twice weekly), neurological disorders, 
behavioral and dietary changes were also recorded as indica-
tors of drug toxicity.
The handling and experimentation of the animals were 
conducted in accordance with the Greek laws (PD 56/2013 and 
Circular 2215/117550/2013) and the guidelines of the European 
Union (2013/63/EU) under a licenced protocol approved by the 
IACUC and Greek authorities (Lisence no. 5542/228006, IACUC; 
Professor Dr N. Pitsikas, Dr A. Zacharioudaki, Dr J. Chloptsios 
and Dr A. Konstantinidis).
Immunohistochemistry. A total of 11 de-identified FFPE 
(formalin-fixed paraffin-embedded) blocks of pancreatic 
cancer tissues, obtained from the archive of the Pathology 
Department of The Leeds Teaching Hospitals Trust (Leeds, 
UK) were stained for Cav-1. All patients provided informed 
consent prior to the collection of the samples and all proce-
dures were approved by and were in compliance with the 
ethical standards of the Leeds Teaching Hospitals NHS Trust 
(R&I Ref. no. CO18/113235). The differential expression of 
Cav-1 between the tumor and stroma in poorly differenti-
ated (PD) and well/moderately differentiated (WD) areas 
was assessed by a pancreatic pathologist (CV). As previously 
described by Witkiewicz et al (30), Cav-1 expression was 
evaluated as follows: 0 for no staining; 1 for weak and/or focal 
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(<10% of the cells) staining; 2 for moderate or strong staining 
(10-50% of the cells); and 3 for moderate or strong staining 
(>50% of the cells).
Immunohistochemical analysis (IHC) of human and 
xenograft pancreatic cancer tissues was performed on 
3‑µm‑thick paraffin‑embedded sections using a rabbit poly-
clonal anti-Cav-1 antibody (dilution 1:200, anti-cav-1 N-20 
rabbit; sc-894; Santa Cruz Biotechnology). Antigen retrieval 
was performed according to the suppliers' instructions. The 
immunoreaction was detected using a goat anti-rabbit-ALP 
(Menarini Diagnostics, Winnersh‑Wokingham, UK) followed 
by 3,3-diaminobenzidine tetrahydrochloride (DAB; Vector 
Laboratories, Peterborough, UK). Negative controls were 
processed by the omission of primary antibody. For histo-
logical evaluation, sections were stained with hematoxylin 
and eosin (H&E; Thermo Fisher Scientific, Loughborough, 
UK). The sections were imaged using an Axioplan Zeiss light 
microscope (Carl Zeiss Ltd., Cambridge, UK) equipped with 
an AxioCam digital camera.
Statistical analysis. Statistical analysis was performed using a 
Student's t-test or one-way ANOVA with Holm-Sidak as a post 
hoc test where multiple comparisons were carried out using 
GraphPad Prism 6.0 software (GraphPad Software, La Jolla, 
USA). Data are presented as the means ± SD. Statistical 
significance was set at P<0.05.
Results
IHC reveals the variable expression of Cav‑1 in the epithelial 
and stromal component of pancreatic cancer tissue specimens. 
We observed heterogeneity in Cav‑1 expression with respect to 
the degree of differentiation. In the well‑differentiated (WD) 
areas of the samples, Cav-1 staining in the cancer cells was 
negative or exhibited a focal/weak protein expression in 9 out 
of the 11 cases. By contrast, the stroma of the WD areas 
exhibited a strong expression of Cav-1 (Fig. 1 and Table I). 
Cancer cells in the poorly differentiated (PD) areas were 
moderately to strongly Cav-1-positive in 6 out of the 7 cases 
examined. Immunostaining was predominantly cytoplasmic, 
while membranous staining was apparent only in the tumor 
cells with clear cell morphology. The fibroblasts were weakly 
stained in the PD areas, particularly in areas where cancer cells 
were strongly positive (Fig. 1A and C). There seemed to be an 
inverse pattern of Cav-1 expression, with strong staining in the 
cancer cells and weak or no staining in the stroma-associated 
fibroblasts or vice versa (Table I).
Generation of pancreatic cancer cells and fibroblasts in which 
Cav‑1 is knocked down. In order to select the most appropriate 
cell line for our hypothesis, we screened several pancreatic 
cell lines for Cav-1 expression (Fig. 2A) and we found that the 
BxPC3 cells expressed the highest levels of Cav‑1. We thus 
selected these cells for use in the subsequent experiments. The 
lentivirus-induced introduction of shRNA into the BXPC3 
cells resulted in a decreased mRNA and protein expression 
of Cav-1, as shown in Fig. 2B and D. The concomitant intro-
duction of GFP allowed for the discrimination and separation 
of cells with the highest viral integration/expression and 
consequent lower Cav-1 expression (named BxPC3shCAV) with 
the aid of cell sorting (Fig. 2F). As a control, the BxPC3mock 
cell line was generated with unaffected levels of Cav-1. 
Lentiviral particles expressing scrambled shRNA (mock) 
did not alter the Cav‑1 levels, confirming that the decreased 
expression of Cav-1 in BxPC3shCAV was due to the specific 
effects of shRNA (Fig. 2B and D). Fibroblasts with silenced 
(hhsFshCAV) or unaffected (hhsFmock) Cav-1 expression were 
generated from hTERT immortalized human skin fibroblasts 
following the methodology described above for the BxPC3 
cells (Fig. 2C and E).
Downregulation of Cav‑1 expression results in a marginal 
increase in DNA synthesis and tumor cell proliferation, and 
in the increased migration/motility of BxPC3 cells. We first 
examined whether Cav-1 downregulation in pancreatic cancer 
cells affected the proliferation rate of these cells. By the SRB 
method and the BrdU DNA incorporation method, beginning 
with an inoculation density of 5,000 cells/well, a moderate 
increase in DNA synthesis (Fig. 3A) and in the proliferation of 
BxPC3shCAV as compared to BxPC3 and BxPC3mock cells were 
observed (Fig. 3B). These results suggest that Cav-1 may, to a 
certain extent, act as negative regulator of the growth of pancre-
atic cancer cells under the prevailing experimental conditions. 
Furthermore, as shown in Fig. 3C, the downregulation of 
Cav‑1 in the BxPC3 cells resulted in a statistically significant 
increase in the migratory capacity of the BxPC3shCAV cells as 
compared to the BxPC3mock cells (P<0.01), suggesting again 
that Cav-1 may act as a brake on the proliferative and migra-
tory capacity of pancreatic cancer cells.
Table I. Caveolin-1 expression in patient archival samples.
 Poorly Moderately/
 differentiated well differentiated
 Cav-1 expression  Cav-1 expression
 -------------------------------------- ----------------------------------------------
Case no. Cancer Stroma Cancer Stroma
  1 3 1 1 3
  2 2 2 0 2
  3 No PD areas 2 3
  4 No PD areas 2 1 but scarce
   stroma
  5 No PD areas 1 3
  6 1 3 0 3
  7 3 2 0 1 but scarce
    stroma
  8 3 1 1 3
  9 2 2 1 3
10 3 1 1 3
11 No PD areas 0 3
Caveolin-1 expression in cancer cells and stroma in well and poorly 
differentiated areas of pancreatic cancer in 11 archival samples. For 
details please see the Materials and methods, immunohistochemistry. 
Cav-1 staining was graded as follows: 0, negative; 1, weak and/or focal 
(<10%); 2, moderate or strong (10-50%); 3, moderate or strong >50%. 
Cav-1, caveolin-1, PD, poorly differentiated. 
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Figure 2. Generation of cells with a modified expression of caveolin‑1. (A) Differential caveolin‑1 expression in expression in 4 cells lines tested. Differential 
protein expression and relative mRNA levels of caveolin‑1 in (B and D) BxPC3 cells and in (C and E) hTERT human skin fibroblasts. (F) Gating strategy for 
sorting the transfected cells. BxPC3shCAV, BxPC3 cells transfected with shRNA against caveolin-1; BxPC3mock, BxPC3 cells transfected with a sequence that 
was not expressed; hhsFshCAV, hTERT human skin fibroblasts transfected with shRNA against caveolin‑1; hhsFmock, hTERT human skin fibroblasts transfected 
with a sequence that was not expressed; GFP, green fluorescent protein; FSC, forward scattering. *P<0.05 and **P<0.01
Figure 1. (A-D) Caveolin-1 (Cav-1) expression in pancreatic cancer cases. (A and B) Cav-1 expression in poorly differentiated pancreatic cases with high 
expression in the cancer cells (thick arrows) and no expression in the stroma (thin arrows). (C and D) In well-differentiated areas of the same tumors shown 
in (A and B), the opposite pattern was observed i.e., a strong expression in the stroma, whereas the cancer cells were negative (representative areas of this 
pattern are shown). H&E staining of these regions is also presented (left panels). (A and C) case 1; (B and D) case 10 (see Table I). Scale bar, 100 µm.
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Cav‑1 downregulation in fibroblasts increases the migratory 
and chemotactic ability of BxPC3 cells. To further determine 
the effects of Cav-1 levels not in the cancer cells, but in the 
context of the tumor microenvironment, a Transwell migra-
tion/chemotaxis assay was performed (Fig. 4) where the effect 
of fibroblasts in which Cav‑1 was silenced on the chemotactic 
migration of normal (non-Cav 1 silenced) BxPC3 cells was 
examined. In this experiment, the silencing of Cav-1 in the 
fibroblasts (hhsFshCAV) resulted in an increased migration of 
BxPC3 cancer cells (60±21%) through the micropores of 
the Transwell as compared to the mock‑infected fibroblasts 
(hhsFmock, P<0.05, paired t-test). These results suggest that 
the absence of Cav‑1 in fibroblasts may favor the metastatic 
potential of tumor cells in the context of the tumor microen-
vironment. As the tumor cells were not in contact with the 
fibroblasts, the secretion of agents from the fibroblasts may 
have acted as chemoattractants to induce the migration of 
tumor cells towards the surrounding stroma.
Effect of Cav‑1 expression on the chemosensitivity of cancer 
cells. To examine the effect of Cav-1 expression on the chemo-
sensitivity of human the pancreatic cancer BxPC3 cells, the 
BxPC3mock and BxPC3shCAV cells were exposed to various 
chemotherapeutic agents i.e., 5‑fluorouracil (5‑FU), gemcitabine, 
doxorubicin, epirubicin, cisplatin, oxaliplatin, docetaxel and 
Paclitaxel. The sensitivity of all 3 cell lines (BxPC3, BxPC3mock 
and BxPC3shCAV) seemed to be unaffected by the levels of 
expression of Cav-1 to the chemotherapeutic agents that were 
tested, as shown by the corresponding growth curves (Fig. 5).
Decreased Cav‑1 levels in the stroma promote the growth 
of BxPC3 tumor xenografts. We then examined whether the 
Figure 3. Silencing of caveolin-1 in BxPC3 cells results in a moderate increase in cellular proliferation and the increased migration of BxPC3 cells. A total 
of 5,000 cells/well for each cell line were inoculated and either (A) the DNA synthesis rate by the incorporation of BrdU or (B) the total cell population using 
the SRB assay, were determined after 48 h of incubation. Bars show the means of 3 independent experiments run in triplicate. (A) **P<0.001 vs. BxPC3 and 
BxPC3mock, one-way ANOVA, Holm-Sidak post hoc test. (B) **P<0.001 vs. BxPC3 and #P<0.05 vs. BxPC3mock, one-way ANOVA, Holm-Sidak post hoc test. 
x-axis labels are the same for A and B. (C) Percentage free area for the wound healing/scratch assay at various time points. Bars represent the means of 
2 independent experiments. **P<0.01, ***P<0.005 and ###P<0.005 vs. BxPC3mock at 5 h. (D-G) Representative images of the wound healing/scratch assay for 
(D and F) BxPC3mock or (E and G) BxPC3shCAV cells at time 0 (D and E, respectively) and 28 h later (F and G, respectively). The red dotted line shows the borders 
of the cell population at the site of the scratch. Photos are representative of 1 out of 2 experiments.
Figure 4. Downregulation of caveolin-1 in fibroblasts potentiates the 
migratory capability of the cancer cells. Changes in the Transwell chemo-
taxis/migration assay for BxPC3 cancer cells in the presence of fibroblasts. 
Bars represent the percentage increase in the migrated population as 
compared to cells migrating in DMEM supplemented with 1% FCS in the 
absence of fibroblasts. The mean of 2 independent experiments ± SD is 
shown. *P<0.05 vs. BxPC3mock in a pairwise t-test.
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protein expression levels of Cav-1 can affect the tumorigenic 
capacity and/or the chemoresistance of BxPC3 in xenografts. 
Towards this aim, we first sought to compare the tumorigenic 
and growth characteristics of the two cell lines, BxPC3mock 
and BxPC3shCAV, when inoculated into NOD/SCID mice. 
The two xenografts from the transfected cells demonstrated 
no difference between the growth rates of BxPC3mock- and 
BxPC3shCAV-derived tumors (Fig. 6).
Following the in vitro observation that low levels of 
fibroblast Cav‑1 expression resulted in increased cancer cell 
motility/migration (Fig. 4), we determined whether fibroblast 
Cav-1 expression can affect the growth of BxPC3 when grown 
as xenografts. As shown in Fig. 7, the co‑injection of fibroblasts 
with BxPC3 cells significantly affected the growth of tumors 
in a Cav-1-dependent manner. The tumors that developed from 
BxPC3 cells co-injected with hhsFmock (BxPC3 + hhsFmock 
tumors) cells exhibited similar growth as the tumors derived 
from the BxPC3 cells alone. However, the co-injection of 
BxPC3 cells with hhsFshCAV (BxPC3 + hhsFshCAV tumors), 
Figure 6. Downregulation of caveolin-1 in BxPC3 cells does not affect the tumor 
growth in the corresponding xenografts. The growth rates of the tumors devel-
oped by the subcutaneous inoculation of 5x106 cells of BxPC3mock and BxPC3shCAV 
in immunocompromised mice are shown. Points represent the average ± SD.
Figure 5. Downregulation of caveolin-1 in cancer cells does not affect the in vitro chemosensitivity of BxPC3 cells. The growth curves of the 3 cell lines 
co-cultured for 48 h with various concentrations of the drugs are presented. Each point represents the mean of 2 independent experiments run in triplicate ± SD. 
Negative values denote toxicity. For details on the calculation of the growth rate, please see the Materials and methods.
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resulted in an almost 3-fold increase in tumor weight compared 
to both the BxPC3- and the BxPC3 + hhsFmock-derived tumors 
(130±98 and 167±42 mg, respectively vs. 360±138 mg for the 
BxPC3 + hhsFshCAV tumors; P<0.01). At 6 days post-inoculation 
of 3x105 BxPC3 cells into NOD/SCID mice, at a 1:1 ratio of 
cancer cells:fibroblasts, the following was observed: No tumor 
development in the BxPC3-only inoculated mice (0/10); 1 tumor 
palpable in 10 mice that received BxPC3 + hhsFmock (1/10), and 
3 tumors palpable in mice that were co-injected with BxPC3 
and hhsFshCAV cells (3/10). A week later, at day 13, the ratio 
was 3/10 for BxPC3 and for BxPC3 + hhsFmock as compared 
to 7/10 for the BxPC3 + hhsFshCAV-derived tumors. Similarly, 
increasing the inoculation density of cancer cells to 1x106 
(cancer cells:fibroblasts ratio: 3:1) resulted in the development 
of tumors in the following numbers of mice: 0/10 for BxPC3, 
1/10 for BxPC3 + hhsFmock and 7/10 for BxPC3 + hhsFshCAV at 
day 6 and 5/10, 6/10 and 9/10 tumors at day 13, respectively 
(data not shown). The post-mortem weights of the tumors that 
had developed by day 28 post-inoculation of the cells revealed a 
substantial difference between the BxPC3-derived tumors that 
developed from the co-injection with hhsFshCAV fibroblasts as 
compared to the BxPC3-only and BxPC3 + hhsFmock-derived 
tumors, both at the cancer cells:fibroblasts ratios of 1:1 and 3:1 
(P<0.05 or 0.01, respectively; Fig. 7). Mice injected with 
fibroblasts alone did not develop any tumors (data not shown).
Finally, to examine the effect of Cav-1 expression in 
fibroblasts on the chemosensitivity of pancreatic cancer cells 
exposed to gemcitabine, co-injection experiments as described 
above were undertaken following the administration of 
gemcitabine. Beginning on day 4 post-cells' inoculation, 
the mice were injected intraperitoneally with either 
100 mg/kg gemcitabine or an equivalent volume of saline 
as the control, on a weekly basis for 3 weeks (till the end of 
the experiment). As shown in Fig. 8, tumors that developed 
from the co-injection of BxPC3 and hhsFshCAV fibroblasts were 
substantially more resistant as compared to those developed 
from the co-inoculation of hhsFmock fibroblasts (P<0.01vs. 
BxPC3 + hhsFmock + gemcitabine). These tumors exhibited no 
Figure 7. Downregulation of caveolin-1 in fibroblasts results in increased 
growth rate of cancer cells. The post-mortem tumor weights for BxPC3 
cells alone or co-injected with either hhsFmock or hhsFshCAV are shown as the 
average of the weights of all tumors ± SD in either a ratio of (A) 1:1 or (B) 3:1 
(BxPC3 vs. hhsF). (A) *P<0.05 vs. the BxPC3 and BxPC3+hhsFmock xenografts. 
(B) **P<0.01 vs. the BxPC3 and BxPC3+hhsFmock. Inserts show representative 
tumors from the 3 groups in each case. Scale bar, 1 cm.
Figure 8. Downregulation of caveolin‑1 in fibroblasts results in the increased 
chemoresistance of BxPC3 pancreatic cancer cells to gemcitabine. The 
(A) volumes and (B) the post mortem tumor weights for BxPC3 cells alone or 
co-injected with either hhsFmock or hhsFshCAV at a ratio of 3:1 (BxPC3 vs. hhsF), 
treated or untreated with gemcitabine are shown as the average ± SD. *P<0.05; 
**P<0.01; ***P<0,001; ****P<0,0001. Insert shows representative tumors from 
the 4 groups as follows: (C) BxPC3 + hhsFmock; (D) BxPC3 + hhsFmock + gem-
citabine; (E) BxPC3 + hhsFshCAV; (F) BxPC3 + hhsFshCAV + gemcitabine. Scale 
bar, 1 cm. GEM; gemcitabine.
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response at all when compared to the corresponding untreated 
tumors (i.e., vs. BxPC3 + hhsFshCAV).
Taken together, these results demonstrate that although 
the levels of Cav-1 seem to have a minor effect on cellular 
proliferation and none regarding the chemosensitivity of 
BxPC3 cancer cells in vitro, the lack of Cav-1 expression in 
fibroblasts within the cancer microenvironment may affect 
more substantially both the growth and chemoresistance of 
the tumor cells.
Immunohistochemical analysis of xenografts does not 
identify differences in the amount of stroma. To determine the 
contribution of the stroma to the tumor weight in xenografts 
from the co-injection experiments of explanted xenografts, 
IHC was performed. The amount of stroma did not differ 
across the experimental conditions, indicating that differences 
in tumor size are not attributed to differences in stromal 
content (data now shown).
Discussion
In this study, we initially observed that there was an inverse 
association between Cav-1 expression in cancer cells and 
stromal fibroblasts. Despite the small number of cases, it 
was consistently observed that in areas of well-differentiated 
tumors, fibroblasts stained strongly for Cav‑1, while cancer 
cells were negative or stained only weakly. By striking 
contrast, in areas of poorly differentiated tumors, the cancer 
cells exhibited a high expression of Cav-1 and were surrounded 
by fibroblasts with a low Cav‑1 expression. These results are in 
accordance with those of previous studies, which linked Cav-1 
expression in cancer cells to poor differentiation (30,36). 
However, to the best of our knowledge, this is the first study 
showing an opposite pattern of Cav-1 expression between 
tumor and stromal cells in pancreatic cancer. These results 
are in agreement with those of a previous study on colorectal 
cancer, reporting the differential expression of Cav-1 between 
stroma and cancer cells (37). Alshenawy and Ali reported that 
the overexpression of Cav-1 in cancer cells was associated with 
adverse prognostic features, while a higher stromal expression 
was associated with small non-metastasizing tumors and thus 
a better prognosis (37). The exact mechanisms behind this 
observation are not yet clear; however, it has been suggested 
that regional differences in hypoxia or acidity may explain 
tumor heterogeneity (38,39).
To determine whether this differential expression of Cav-1 
in cancer cells and the surrounding stroma have an influence 
on tumor biology, we examined the effects of decreased levels 
of Cav-1 expression on cell proliferation and chemosensitivity 
in a human pancreatic cancer cell line with a high Cav-1 
expression. Four commonly used human pancreatic cancer 
cell lines, i.e., BxPC3 (moderate to poor differentiation) (40), 
AsPC1, PANC-1 and MIAPaCa-2 (all 3 of poor differentiation) 
were tested for caveolin expression (Fig. 1A). In our labora-
tory, BxPC3 cells were found to express the highest levels of 
Cav-1 with the MIAPaCa-2 cells showing minimal expression. 
We herein though need to point out that the data from previous 
studies regarding the expression of Cav-1 in MIAPaCa-2 cells 
have been controversial, as in the study by Salem et al (29), 
it was reported a low expression of the protein, in agreement 
with our data, while Chatterjee et al (36) reported high levels 
of Cav-1 expression in MIAPaCa-2 cells. In studies using mice 
to compare these cell lines for their tumorigenicity (xenograft 
studies), it was suggested that BxPC3 may be more aggressive 
as compared to PANC1, AsPC1 and MIAPaCa-2 cells (40). 
Thus, we decided to proceed with the BxPC3 cell line in this 
study.
The results revealed that the decreased expression of Cav-1 
only marginally increased the cellular proliferation and DNA 
synthesis, suggesting that Cav-1 may act as a tumor suppressor 
to a certain extent. The downregulation of the protein resulted 
in the increased migratory capability of the BxPC3 cancer cell 
line in the wound healing assay. However, we need to point 
out herein that this effect may be the result of the increased 
proliferation of the cells.
Our results are in agreement with those reported in other 
studies regarding the role of Cav-1 in the migration and inva-
sion of pancreatic cancer cell lines (16,29,41). In support of 
the inhibitory effects of Cav-1 on the migration and invasion 
of pancreatic cancer cells, Han and Zhu (41) reported that the 
knockdown of Cav-1 promoted the activity of matrix metal-
loprotease (MMP)2 and 9. However, these observations are 
not supported by Chatterjee et al (36), who reported opposite 
results, suggesting that the overexpression of Cav-1 may act as 
a promoting factor for cancer cell proliferation, invasion and 
migration. The use of different cell lines or other methods to 
down- or upregulate Cav-1 and to address migration and inva-
sion may potentially explain these differences.
Cav-1 expression in pancreatic cancer cells has been related 
to a decreased sensitivity to ionizing radiation (42), while 
chemosensitivity is preserved through EMT inhibition (29). 
In this study, a variety of chemotherapeutic agents commonly 
used in pancreatic cancer were tested in vitro. It was demon-
strated that lower levels of the protein did not affect the in vitro 
chemosensitivity of the BxPC3 cells to all the tested chemo-
therapeutics. Finally, in an effort to shed some light on the 
capacity of the Cav-1 to affect tumorigenicity of cancer cells, 
we performed an in vivo experiment by injecting BxPC3mock 
and BxPC3shCAV cells into SCID mice. This experiment clearly 
demonstrated that Cav-1 expression in the injected cells played 
no role in overall tumor growth.
Tumor development involves a stromal microenvironment 
that contains fibroblasts, macrophages and other cell types. 
It is now widely accepted that cancer‑associated fibroblasts 
play a major role in both tumor initiation and progression. In 
this context, it has been proposed that the absence of Cav-1 
may be a characteristic of a cancer-associated fibroblast 
phenotype (43,44). Pancreatic cancer stromal cells have been 
shown to express low levels of Cav-1 (11), and in a cohort of 
45 patients, the expression levels of this protein were found to 
be related with the TNM stage, HER-2/neu amplification and 
the overall prognosis of the disease (21).
We then set out to determine whether differences in Cav‑1 
expression in the tumor microenvironment have a direct influ-
ence on the phenotype of pancreatic cancer cells. Human 
dermal fibroblasts, manipulated to express decreased levels of 
Cav-1 compared to the control, induced the increased inva-
sion of pancreatic cancer cells in vitro. Since the two types of 
cells were not in direct contact, these findings suggest that the 
increased invasiveness of the tumor cells may be driven by 
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secreted chemotactic agents. Such an effect has already been 
demonstrated in breast cancer (45); however, to the best of our 
knowledge, this is the first report to demonstrate that Cav‑1 
silencing in fibroblasts may directly regulate the invasiveness 
of pancreatic tumor cells in a paracrine manner. In support of 
this observation, it has been suggested that cancer-associated 
fibroblasts (CAFs) with a decreased expression of Cav‑1 may 
provide nutritional support to the cancer cells by the phenom-
enon of reverse Warburg effect (46).
Subsequently, we examined the in vivo effect of Cav-1 
silencing in fibroblasts. From these in vivo experiments it was 
evident that the cancer cells gained developmental advantage 
when they were co‑injected with fibroblasts that had a decreased 
expression of Cav-1. Indeed, an almost 3-fold increase in tumor 
weight was observed in the tumors that were developed by the 
co‑injection of fibroblasts with silenced Cav‑1 and BxPC3 
cells, as compared to BxPC3- and hhsFmock-derived tumors. 
These results outweighed the need to perform co-culture 
experiments in vitro. Similar results have been reported by 
Capozza et al (47) in a murine model of melanoma, in which 
the downregulation of Cav-1 in CAFs promoted the develop-
ment of melanoma cells through paracrine Sonic Hedgehog 
signaling. Similarly, Bonuccelli et al (45) reported that fibro-
blasts with silenced Cav-1 expression enhanced the growth of 
MDA-MB231 breast cancer xenografts.
Once we obtained clear evidence that the downregulation 
of Cav-1 expression in fibroblasts could provide a growth 
advantage to cancer cells in vivo, we set out to determine 
whether the absence of Cav-1 in fibroblasts of the tumor 
microenvironment may play a role in the development of 
chemoresistance. According to our findings, the downregula-
tion of Cav‑1 in stromal fibroblasts triggered the development 
of chemoresistance when mice were treated with gemcitabine. 
Indeed, tumors derived from the inoculation with fibroblasts 
with silenced Cav-1 expression and BxPC3 cells alone did not 
respond to gemcitabine chemotherapy. These data suggest a 
possible link between stromal Cav-1 expression and chemo-
resistance to gemcitabine, which is a standard drug used in 
the treatment of pancreatic cancer. In accordance to our initial 
clinical observation, we could argue that hhsFshCAV represent 
the stroma in the poorly differentiated pancreatic cancer 
area and the fibroblasts with a decreased expression of Cav‑1 
provide survival gain and chemoresistance to the pancreatic 
cancer cells.
The stroma has been regarded for a long time as a poten-
tial barrier to the diffusion of chemotherapeutic agents into 
tumors. Strategies to deplete the tumor-related stroma have 
therefore been considered as a rational approach to improving 
response to chemotherapy (48). Unfortunately, this approach 
has not been translated into successful clinical trials. Recent 
studies have actually suggested that stroma depletion may 
accelerate cancer development, thus reducing survival (49,50). 
Furthermore, the recent observation that CAFs lead the 
scavenging of gemcitabine is a further possible mechanism 
of treatment failure in pancreatic cancer (51). Methods to 
restore the stromal expression of Cav-1 (52) may represent 
another potential therapeutic strategy for pancreatic cancer by 
increasing the sensitivity to chemotherapy.
Despite some limitations to our study, mainly pertaining 
to the use of dermal immortalized fibroblasts instead of CAFs 
and the use of a single cell line, our data support the hypothesis 
that Cav-1 expression in the stromal component of pancreatic 
cancer may influence cancer cell growth and the development 
of resistance to chemotherapy. Nevertheless, xenograft models 
with the use of non‑tumor associated fibroblasts have been used 
successfully for the study of chemotherapy resistance (53). 
Our group aims to further shed light onto the role of Cav-1 
in pancreatic cancer by developing patient derived xenografts 
and trying to isolate cancer‑associated normal fibroblasts that 
could be used to address the role of Cav-1 in clinically more 
relevant settings.
In conclusion, the data presented herein suggest that 
Cav-1 expressed in the stroma rather than in the tumor cells 
has an impact on tumor development and chemoresistance in 
pancreatic cancer. However, further studies are warranted to 
investigate whether the manipulation of Cav-1 expression in 
CAFs may represent a valid and effective therapeutic approach 
in pancreatic cancer.
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